

Part VI: Summary of the risk management plan

Summary of risk management plan for Ivacaftor Bioeel 150 mg comprimate filmate (ivacaftor)

This is a summary of the risk management plan (RMP) for Ivacaftor Bioeel. The RMP details important risks of Ivacaftor Bioeel, how these risks can be minimised, and how more information will be obtained about Ivacaftor Bioeel's risks and uncertainties (missing information).

Ivacaftor Bioeel's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Ivacaftor Bioeel should be used.

Important new concerns or changes to the current ones will be included in updates of Ivacaftor Bioeel's RMP.

I. The medicine and what it is used for

Ivacaftor Bioeel is authorised (see SmPC for the full indication):

- as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (CF) who have an *R117H CFTR* mutation or one of the following gating (class III) mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: *G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N* or *S549R*
- in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (CF) who are homozygous for the *F508del* mutation or who are heterozygous for the *F508del* mutation and have one of the following mutations in the CFTR gene: *P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272-26A→G, and 3849+10kbC→T*
- in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (CF) who have at least one non-Class I mutation in the CFTR gene.

It contains ivacaftor as the active substance and it is given by oral route of administration.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Ivacaftor Bioeel, together with measures to minimise such risks and the proposed studies for learning more about Ivacaftor Bioeel's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;

- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

If important information that may affect the safe use of Ivacaftor Bioeel is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of Ivacaftor Bioeel are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Ivacaftor Bioeel. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

List of important risks and missing information	
Important identified risks	- None
Important potential risks	- Hepatotoxicity - Cataract
Missing information	- Use in pregnant and lactating women - Indicated use in children less than 6 years

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Ivacaftor Bioeel.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Ivacaftor Bioeel.